Trial Profile
Randomized comparison of adjuvant Docetaxel / Cyclophosphamide with sequential adjuvant EC / Docetaxel chemotherapy in patients with HER2/neu negative early breast cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Mar 2022
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Cyclophosphamide; Epirubicin
- Indications Early breast cancer; HER2 negative breast cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms PLAN B
- 22 Feb 2022 Results of a pooled analysis (PlanB and SUCCESS C studies) assessing the impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer published in the British Journal of Cancer
- 01 Oct 2017 According to results published in the Breast Cancer Research and Treatment, a protocol was amended in Aug 2009 to recommend endocrine therapy alone for pN0, pN1 locally HR positive patients with RS less than or equal to 11.
- 07 Jun 2017 Status changed from active, no longer recruiting to completed.